GlassScriptPhysician profile
Lynn R Thibodeau
NPI 1811992696
$10,172.34
in general payments reported to CMS, 2019-2025
64 companies · $2,719 in 2025
The $2,719 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,530 · 2022: $1,731 · 2023: $1,683 · 2024: $2,509 · 2025: $2,719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,911.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,911.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $879.68 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $761.79 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $734.68 | 2021-2025 | Imfinzi, Enhertu, Calquence |
| Daiichi Sankyo INC. | $597.38 | 2021-2025 | Enhertu, Datroway, Injectafer |
| E.R. Squibb & Sons, L.L.C. | $389.08 | 2021-2025 | Opdivo |
| Janssen Biotech, INC. | $336.89 | 2021-2025 | Rybrevant, Darzalex, Erleada |
| Gilead Sciences, INC. | $323.70 | 2022-2025 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $322.70 | 2021-2025 | |
| Glaxosmithkline, LLC. | $310.54 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Seagen INC. | $305.26 | 2021-2023 | Tukysa, Adcetris, Tivdak |
| Eisai INC. | $304.39 | 2021-2025 | |
| Astellas Pharma US INC | $287.66 | 2021-2025 | Vyloy, Xospata, Padcev |
| Genzyme Corporation | $282.39 | 2021-2025 | |
| Pfizer INC. | $269.35 | 2022-2025 | |
| Celgene Corporation | $265.42 | 2021-2025 | Reblozyl, Opdualag |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $245.36 | 2021-2025 | Jakafi, Pemazyre, Monjuvi |
| Lilly USA, LLC | $220.38 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Taiho Oncology, INC. | $215.13 | 2021-2025 | |
| Amgen INC. | $205.87 | 2021-2023 | Lumakras, Kyprolis, Blincyto |
| Takeda Pharmaceuticals U.S.A., INC. | $201.48 | 2022-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Array Biopharma INC | $184.59 | 2022-2025 | Braftovi, Mektovi, Tukysa |
| Exelixis INC. | $178.21 | 2022-2025 | Cabometyx |
| Genentech USA, INC. | $163.25 | 2021-2025 | Polivy, Phesgo, Perjeta |
| Ipsen Biopharmaceuticals, INC | $132.06 | 2021-2025 | Somatuline Depot, Onivyde |
| Tersera Therapeutics LLC | $128.16 | 2023-2025 | Zoladex |
| Abbvie INC. | $126.78 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $122.36 | 2021-2025 | Libtayo |
| Foundation Medicine, INC. | $108.13 | 2021 | |
| Servier Pharmaceuticals LLC | $104.20 | 2021-2025 | |
| Immunocore Limited | $96.46 | 2025 | Kimmtrak |
| Sobi, INC | $93.00 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $92.91 | 2021-2024 | |
| Alexion Pharmaceuticals, INC. | $87.63 | 2021-2023 | Ultomiris |
| Mirati Therapeutics, INC. | $81.73 | 2023-2024 | Krazati |
| Jazz Pharmaceuticals INC. | $67.58 | 2022-2025 | |
| Epizyme, INC. | $66.87 | 2021-2022 | |
| Stemline Therapeutics INC. | $66.06 | 2023-2025 | Orserdu |
| Kite Pharma, INC. | $63.74 | 2021 | |
| Genmab U.S., INC. | $59.90 | 2025 | Epkinly |
| Pharmacosmos Therapeutics INC. | $56.07 | 2024-2025 | Cosela, Monoferric |
| Emd Serono, INC. | $53.82 | 2025 | |
| Beone Medicines USA, INC. | $51.93 | 2025 | Brukinsa, Tevimbra |
| Agios Pharmaceuticals, INC. | $46.38 | 2024-2025 | Pyrukynd |
| Azurity Pharmaceuticals, INC. | $39.43 | 2025 | Danziten |
| Deciphera Pharmaceuticals INC. | $37.73 | 2022-2023 | Qinlock |
| Heron Therapeutics, INC. | $34.09 | 2021 | |
| Sumitomo Pharma America, INC. | $31.47 | 2023-2024 | Orgovyx |
| Puma Biotechnology, INC. | $30.41 | 2022 | |
| Csl Behring | $28.60 | 2023 | Afstyla, Idelvion |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.39 | 2022 | |
| Apellis Pharmaceuticals, INC. | $27.09 | 2022 | |
| Global Blood Therapeutics, INC. | $25.31 | 2021-2022 | |
| G1 Therapeutics, INC. | $22.66 | 2022 | |
| Emmaus Medical, INC. | $21.66 | 2021 | |
| Pharmaessentia USA Corporation | $21.57 | 2022 | |
| Blue Earth Diagnostics | $20.83 | 2021 | |
| Tg Therapeutics, INC. | $17.14 | 2022 | |
| Rigel Pharmaceuticals, INC. | $15.66 | 2022 | |
| Sun Pharmaceutical Industries INC. | $15.25 | 2021 | |
| Adc Therapeutics America, INC. | $14.86 | 2025 | |
| Novocure INC. | $13.69 | 2025 | Optune Gio |
| Pharmacyclics LLC, An Abbvie Company | $12.49 | 2022 | |
| Myovant Sciences INC. | $11.92 | 2022 | |
| Dendreon Pharmaceuticals LLC | $11.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Thibodeau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.